<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631393</url>
  </required_header>
  <id_info>
    <org_study_id>EPM 2020-02642</org_study_id>
    <nct_id>NCT04631393</nct_id>
  </id_info>
  <brief_title>Patient-controlled Sedation in Port Implantation (PACSPI-1)</brief_title>
  <acronym>PACSPI-1</acronym>
  <official_title>Patient-controlled Sedation in Port Implantation (PACSPI-1)-a Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stefanie Seifert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Jönköping County</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, observational study is to assess the feasibility of&#xD;
      patient-controlled sedation (PCS) for implantation of subcutaneous venous ports (SVP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this trial is to study the feasibility of (PCS) with propofol and&#xD;
      alfentanil during SVP implantation.&#xD;
&#xD;
      Participants included in the study are able to administer a combination of propofol and&#xD;
      alfentanil using a patient-controlled sedation pump. This allows the patient to self-control&#xD;
      their sedation/analgesia during SVP implantation. The pump enables the patient via a&#xD;
      hand-held button to trigger the release of a single bolus. A bolus of 0.5ml programmed into&#xD;
      the pump contains a combination of 4.5mg propofol and 25µg alfentanil and is administered&#xD;
      under a 7 second period resulting in a maximal amount of 8 bolus doses per minute.&#xD;
&#xD;
      Each SVP implantation procedure is separated into four time points at which sedation scores&#xD;
      are recorded. Patients are monitored by anaesthesia staff and SVP implantation is performed&#xD;
      by an anaesthesiologist according to hospital protocol.&#xD;
&#xD;
      Participants are asked to fill in a written questionnaire to indicate pain score and&#xD;
      satisfaction with the procedure when ready for discharge.&#xD;
&#xD;
      Adverse events, time consumption and operators satisfaction with implantation conditions are&#xD;
      recorded periprocedural.&#xD;
&#xD;
      The result of this trial will provide guidance for a larger randomized trial (PACSPI-2)&#xD;
      comparing several clinically relevant aspects of the use of PCS and local anesthesia (LA)&#xD;
      versus LA alone during SVP implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Actual">October 15, 2021</completion_date>
  <primary_completion_date type="Actual">October 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participants maximal pain level</measure>
    <time_frame>10 minutes before discharge from recovery area</time_frame>
    <description>Participants assessment of maximal pain level experienced during the procedure using a numeric rating scale from 0-10 (0=no pain, 10=worst pain I know) on patient questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural time consumption</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>From procedure start (local anesthesia injection) until end of procedure (last suture).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delivered doses of propofol and alfentanil</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>The total dose of given sedation and analgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grading of implantation conditions by the implanting physician</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>The port-implanting physicians assessment of implantation conditions during the procedure on a numeric rating scale (0=worst possible, 10= best possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants overall satisfaction</measure>
    <time_frame>10 minutes before discharge from recovery area</time_frame>
    <description>Participants assessment of overall satisfaction experienced during the procedure using a numeric rating scale from 0-10 (0=not satisfied at all, 10=very satisfied) on patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants satisfaction with staff</measure>
    <time_frame>10 minutes before discharge from recovery area</time_frame>
    <description>Participants assessment of satisfaction with the staff using a numeric rating scale from 0-10 (0=not satisfied at all, 10=very satisfied) on patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants maximal pain from arm where infusion is</measure>
    <time_frame>10 minutes before discharge from recovery area</time_frame>
    <description>Participants assessment of pain from arm with the infusion using a numeric rating scale from 0-10 (0=no pain, 10=worst pain I know) on patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants satisfaction with pain treatment during implantation</measure>
    <time_frame>10 minutes before discharge from recovery area</time_frame>
    <description>Participants assessment of satisfaction with pain treatment on a numeric rating scale from 0-10 (0=not satisfied at all, 10=very satisfied) on patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants evaluation of the importance of receiving sedatives during the procedure</measure>
    <time_frame>10 minutes before discharge from recovery area</time_frame>
    <description>Participants assessment of the importance of receiving sedatives on a numeric rating scale from 0-10 (0=not important, 10=very important) on patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants evaluation of the importance of being in control of sedation administration</measure>
    <time_frame>10 minutes before discharge from recovery area</time_frame>
    <description>Participants assessment of the importance of being in control of sedation administration on a numeric rating scale from 0-10 (0=not important, 10=very important) on patient questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Arterial puncture</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>Physicians assessment after completion of procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pneumothorax</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>Physicians assessment after completion of procedure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bradycardia</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>Defined as heart &lt; 40/minutes during the procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoxia</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>Defined as Oxygen saturation &lt;90% or significant drop from baseline (&gt;5% SaO2 drop) during the procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Airway intervention (Chin lift)</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>Defined as intervention by staff with chin lift during the procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>after completion of procedure</time_frame>
    <description>Defined as respiratory rate &lt;8/minute during the procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Sedation score at time points T1-T4</measure>
    <time_frame>during procedure at time point T1: sterile skin prepping; T2: local anaesthetic injection; T3: tunneling procedure; T4: draping removal</time_frame>
    <description>Depth of sedation measured by Observer Assessment of Alertness/Sedation Scale OAAS</description>
  </other_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Pain</condition>
  <condition>Patient Satisfaction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Alfentanil</intervention_name>
    <description>Propofol and Alfentanil are self-administered by the participant.</description>
    <other_name>Propofol/Alfentanil self-administration</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients ≥18 years scheduled for SVP implantation at Ryhov County Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Adult patients (≥18 years) scheduled for SVP implantation at Ryhov County Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to operate the PCS apparatus,&#xD;
&#xD;
          -  Inability to communicate in Scandinavian languages.&#xD;
&#xD;
          -  Patients who require general anaesthesia or patients eligible for local anaesthesia&#xD;
             only (i.e. severe sleep apnea).&#xD;
&#xD;
          -  Propofol or alfentanil allergy.&#xD;
&#xD;
          -  Intake of food (or clear fluids) within six (or two) hours prior to the procedure.&#xD;
&#xD;
          -  Failure to achieve peripheral vascular access.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaretha Stenmarker, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Region Jönköping County</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Länssjukhuset Ryhov</name>
      <address>
        <city>Jönköping</city>
        <zip>55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Taxbro K, Hammarskjöld F, Thelin B, Lewin F, Hagman H, Hanberger H, Berg S. Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial. Br J Anaesth. 2019 Jun;122(6):734-741. doi: 10.1016/j.bja.2019.01.038. Epub 2019 Apr 17.</citation>
    <PMID>31005243</PMID>
  </reference>
  <reference>
    <citation>Clements W, Sneddon D, Kavnoudias H, Joseph T, Goh GS, Koukounaras J, Snow T. Randomized and controlled study comparing patient controlled and radiologist controlled intra-procedural conscious sedation, using midazolam and fentanyl, for patients undergoing insertion of a central venous line. J Med Imaging Radiat Oncol. 2018 Dec;62(6):781-788. doi: 10.1111/1754-9485.12817. Epub 2018 Oct 8.</citation>
    <PMID>30295410</PMID>
  </reference>
  <reference>
    <citation>Kreienbühl L, Elia N, Pfeil-Beun E, Walder B, Tramèr MR. Patient-Controlled Versus Clinician-Controlled Sedation With Propofol: Systematic Review and Meta-analysis With Trial Sequential Analyses. Anesth Analg. 2018 Oct;127(4):873-880. doi: 10.1213/ANE.0000000000003361.</citation>
    <PMID>29750696</PMID>
  </reference>
  <reference>
    <citation>Grossmann B, Nilsson A, Sjöberg F, Nilsson L. Patient-controlled Sedation During Flexible Bronchoscopy: A Randomized Controlled Trial. J Bronchology Interv Pulmonol. 2020 Apr;27(2):77-85. doi: 10.1097/LBR.0000000000000610.</citation>
    <PMID>31478938</PMID>
  </reference>
  <results_reference>
    <citation>Taxbro K, Berg S, Hammarskjöld F, Hanberger H, Malmvall BE. A prospective observational study on 249 subcutaneous central vein access ports in a Swedish county hospital. Acta Oncol. 2013 Jun;52(5):893-901. doi: 10.3109/0284186X.2013.770601. Epub 2013 Feb 22.</citation>
    <PMID>23432403</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Region Jönköping County</investigator_affiliation>
    <investigator_full_name>Stefanie Seifert</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>patient-controlled sedation</keyword>
  <keyword>totally implantable venous access devices</keyword>
  <keyword>subcutaneous implanted venous port</keyword>
  <keyword>local anesthesia</keyword>
  <keyword>propofol</keyword>
  <keyword>alfentanil</keyword>
  <keyword>indwelling catheter</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication will be available for sharing on request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The supporting information will be available from november 2020 until 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Requests for sharing IPD that underlie results in a publication can be made to the principal investigator.&#xD;
The supporting information will be available on researchgate.net during the described time frame.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

